Stock Analysis on Net

Allergan Inc. (NYSE:AGN.)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 19, 2015.

Analysis of Inventory

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Inventory Disclosure

Allergan Inc., balance sheet: inventory

US$ in thousands

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Finished products
Work in process
Raw materials
Inventories

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).


Finished Products
Finished products exhibited a generally upward trend over the five-year period, increasing from $148.2 million in 2010 to $188.3 million in 2014. Although there was a slight decline between 2012 and 2013, the overall trajectory suggests growth in this inventory category.
Work in Process
Work in process inventory showed a gradual increase from $41.1 million in 2010 to $50.5 million in 2014. The values rose steadily each year except for a minor dip between 2010 and 2011, indicating ongoing investment or accumulation in production phases.
Raw Materials
Raw materials inventory displayed fluctuations, growing from $40.1 million in 2010 to a peak of $61.2 million in 2013 before declining somewhat to $57.2 million in 2014. This suggests some volatility in procurement or usage patterns of raw materials.
Inventories (Total)
Total inventories increased consistently from $229.4 million in 2010 to $296.0 million in 2014. This steady rise highlights an expansion in overall inventory holdings, which may reflect business growth or changes in inventory management strategy.